A pivotal clinical readout could clear the way for uniQure’s experimental Huntington’s treatment, potentially turning it into one of the first options aimed at slowing the disease rather than just treating symptoms. But the whole story leans heavily on one program, with safety, manufacturing handoffs, and regulator decisions all capable of derailing the timeline.Read more
uniQure is pushing gene therapies for serious brain disorders, but tougher regulators and lingering safety worries could slow its lead program even as early results look promising. See why the company’s long runway and big unmet needs come with real risks around trials, pricing, and competition.Read more
Catalysts About uniQure uniQure develops gene therapies targeting serious neurological and rare metabolic diseases. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
